Renal damage is not improved by blockade of endothelin receptors in primary renin-dependent hypertension

Journal of Hypertension

Volumn 21, Issue 12, 2003, Pages 2389-2397

  Rothermund, Lars ^a   Kossmehl, Peter ^a   Neumayer, Hans H ^a   Paul, Martin ^a   Kreutz, Reinhold ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

AT1 receptor; Endothelin; Endothelin receptors; Hypertension; Proteinuria; Renin

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DARUSENTAN; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; EPROSARTAN; LU 420627; RENIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HYPERTENSION; KIDNEY; KIDNEY INJURY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; RENAL PROTECTION; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TRANSGENIC ANIMAL;

EID: 1442348079     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200312000-00028     Document Type: Article

References (67)

1. Benigni A, Perico N, Remuzzi G. Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Curr Opin Nephrol Hypertens 2001; 10:1-6.
2. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens 1998; 16:1891-1895.
3. Anderson S, Jung FF, Ingelfinger JR. Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265:F477-F486.
4. Bohrer MP, Deen WM, Robertson CR, Brenner BM. Mechanism of angiotensin II-induced proteinuria in the rat. Am J Physiol 1977; 233: F13-F21.
5. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384-394.
6. Anderson S, Rennke HG, Brenner BM. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77:1993-2000.
7. Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925-1930.
8. Remuzzi A, Puntorieri S, Battaglia C, Bertani T, Remuzzi G. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat. J Clin Invest 1990; 85:541-549.
9. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene-morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41:24-36.
10. Gross V, Roman RJ, Cowley AWJ. Abnormal pressure-natriuresis in transgenic renin gene rats. J Hypertens 1994; 12:1029-1034.
11. Springate JE, Feld LG, Ganten D. Renal function in hypertensive rats transgenic for mouse renin gene. Am J Physiol 1994; 266:F731-F737
12. Teisman AC, Pinto YM, Buikema H, Flesch M, Bohm M, Paul M, et al. Dissociation of blood pressure reduction from end-organ damage in TGR(mREN2)27 transgenic hypertensive rats. J Hypertens 1998; 16:1759-1765.
13. Nakov R, Pfarr E, Eberle S. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15: 583-589.
14. 2+ handling in hypertensive transgenic rats overexpressing the Ren2 gene. J Hypertens 2001; 19: 1465-1472.
15. Kreutz R, Kovacevic L, Schulz A, Rothermund L, Ketteler M, Paul M. Effect of high NaCl diet on spontaneous hypertension in a genetic rat model with reduced nephron number. J Hypertens 2000; 18:777-782.
16. Schulz A, Litfin A, Kossmehl P, Kreutz R. Genetic dissection of increased urinary albumin excretion in the munich wistar fromter rat. J Am Soc Nephrol 2002; 13:2706-2714.
17. 7 Rothermund L, Luckert S, Kossmehl P, Paul M, Kreutz R. Renal endothelin ET(A)/ET(B) receptor imbalance differentiates salt-sensitive from salt-resistant spontaneous hypertension. Hypertension 2001; 37:275-280.
18. Kreutz R, Struk B, Rubattu S, Hubner N, Szpirer J, Szpirer C, et al. Role of the alpha-, beta-, and gamma-subunits of epithelial sodium channel in a model of polygenic hypertension. Hypertension 1997; 29:131-136.
19. Hahn AW, Resink TJ, Scott-Burden T, Powell J, Dohi Y, Buhler FR. Stimulation of endothelin mRNA and secretion in rat vascular smooth muscle cells: a novel autocrine function. Cell Regulat 1990; 1:649-659.
20. Resink TJ, Hahn AW, Scott-Burden T, Powell J, Weber E, Buhler FR. Inducible endothelin mRNA expression and peptide secretion in cultured human vascular smooth muscle cells. Biochem Biophys Res Commun 1990; 168:1303-1310.
21. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992; 19:753-757.
22. Chua BH, Chua CC, Diglio CA, Siu BB. Regulation of endothelin-1 mRNA by angiotensin II in rat heart endothelial cells. Biochim Biophys Acta 1993; 1178:201-206.
23. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997; 96: 1593-1597.
24. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997;30:29-34.
25. Zoja C, Morigi M, Figliuzzi M, Bruzzi I, Oldroyd S, Benigni A, et al. Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. Am J Kidney Dis 1995; 26:934-941.
26. Achmad TH, Rao GS. Chemotaxis of human blood monocytes toward endothelin-1 and the influence of calcium channel blockers. Biochem Biophys Res Commun 1992; 189:994-1000.
27. Orisio S, Benigni A, Bruzzi I, Coma D, Perico N, Zoja C, et al. Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney Int 1993; 43:354-358.
28. Hocher B, Liefeldt L, Thone-Reineke C, Orzechowski HD, Distler A, Bauer C, et al. Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 1996; 28: 196-201.
29. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99:1380-1389.
30. Rossi GP, Sacchetto A, Cesari M, Pessina AC. Interactions between endothelin-1 and the renin-angiotensin-aldosterone system. Cardiovasc Res 1999;43:300-307.
31. Muller DN, Mullally A, Dechend R, Park JK, Fiebeler A, Pilz B, et al. Endothelin-converting enzyme inhibition ameliorates angiotensin II-induced cardiac damage. Hypertension 2002; 40:840-846.
32. Rossi GP, Sacchetto A, Rizzoni D, Bova S, Porteri E, Mazzocchi G, et al. Blockade of angiotensin II type 1 receptor and not of endothelin receptor prevents hypertension and cardiovascular disease in transgenic (mREN2)27 rats via adrenocortical steroid-independent mechanisms. Arterioscler Thromb Vasc Biol 2000; 20:949-956.
33. Li JS, Knafo L, Turgeon A, Garcia R, Schiffrin EL. Effect of endothelin antagonism on blood pressure and vascular structure in renovascular hypertensive rats. Am J Physiol 1996; 271:H88-H93.
34. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, et al. Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999; 33:816-822.
35. Sventek P, Turgeon A, Garcia R, Schiffrin EL. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney, one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J Hypertens 1996; 14:57-64.
36. Muller DN, Mervaala EM, Schmidt F, Park JK, Dechend R, Genersch E, et al. Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage. Hypertension 2000; 36: 282-290.
37. Rothermund L, Pinto YM, Hocher B, Vetter R, Leggewie S, Kossmehl P, et al. Cardiac endothelin system impairs left ventricular function in renin-dependent hypertension via decreased sarcoplasmic reticulum Ca(2+) uptake. Circulation 2000; 102:1582-1588.
38. Benigni A, Zoja C, Coma D, Orisio S, Longaretti L, Bertani T, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44:440-444.
39. Orth SR, Esslinger JP, Amann K, Schwarz U, Raschack M, Ritz E. Nephroprotection of an ET(A)-receptor blocker (LU 135252) in salt-loaded uninephrectomized stroke-prone spontaneously hypertensive rats. Hypertension 1998; 31:995-1001.
40. Nakamura T, Ebihara I, Tomino Y, Koide H. Effect of a specific endothelin A receptor antagonist on murine lupus nephritis. Kidney Int 1995; 47:481-489.
41. Suga S, Yasui N, Yoshihara F, Horio T, Kawano Y, Kangawa K, et al. Endothelin a receptor blockade and endothelin B receptor blockade improve hypokalemic nephropathy by different mechanisms. J Am Soc Nephrol 2003; 14:397-406.
42. Benigni A, Zola C, Coma D, Orisio S, Facchinetti D, Benati L, et al. Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. Am J Kidney Dis 1996; 27:416-423.
43. Gomez-Garre D, Largo R, Liu XH, Gutierrez S, Lopez-Armada MJ, Palacios I, et al. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int 1996; 50:962-972.
44. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998; 47:450-456.
45. Braun C, Conzelmann T, Vetter S, Schaub M, Back WE, Yard B, et al. Prevention of chronic renal allograft rejection in rats with an oral endothelin A receptor antagonist. Transplantation 1999; 68:739-746.
46. Orth SR, Odoni G, Amann K, Strzelczyk P, Raschack M, Ritz E. The ET(A) receptor blocker LU 135252 prevents chronic transplant nephropathy in the 'Fisher to Lewis' model. J Am Soc Nephrol 1999; 10:387-391.
47. Rothermund L, Traupe T, Dieterich M, Kossmehl P, Yagil C, Yagil Y, et al. Nephroprotective effects of the endothelin ETA receptor antagonist darusentan in salt-sensitive genetic hypertension. Eur J Pharmacol 2003; 468:209-216.
48. Kirchengast M, Munter K. Endothelin-1 and endothelin receptor antagonists in cardiovascular remodeling. Proc Soc Exp Biol Med 1999; 221:312-325.
49. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329:1456-1462.
50. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
51. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
52. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
53. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334:939-945.
54. Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin-a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990; 87: 4473-4475.
55. Butler WT. Structural and functional domains of osteopontin. Ann NY Acad Sci 1995; 760:6-11.
56. Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between CD44 and osteopontin (Eta-1). Science 1996; 271:509-512.
57. Pichler R, Giachelli CM, Lombardi D, Pippin J, Gordon K, Alpers CE, et al. Tubulointerstitial disease in glomerulonephritis. Potential role of osteopontin (uropontin). Am J Pathol 1994; 144:915-926.
58. Giachelli CM, Pichler R, Lombardi D, Denhardt DT, Alpers CE, Schwartz SM, et al. Osteopontin expression in angiotensin II-induced tubulointerstitial nephritis. Kidney Int 1994; 45:515-524.
59. Pichler RH, Franceschini N, Young BA, Hugo C, Andoh TF, Burdmann EA, et al. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6:1186-1196.
60. Diamond JR, Kreisberg R, Evans R, Nguyen TA, Ricardo SD. Regulation of proximal tubular osteopontin in experimental hydronephrosis in the rat. Kidney Int 1998; 54:1501-1509.
61. Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995; 47:1546-1557.
62. Kleinman JG, Worcester EM, Beshensky AM, Sheridan AM, Bonventre JV, Brown D. Upregulation of osteopontin expression by ischemia in rat kidney. Ann NY Acad Sci 1995; 760:321-323.
63. Wuthrich RP, Fan X, Ritthaler T, Sibalic V, Yu DJ, Loffing J, et al. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(lpr) mice with lupus nephritis. Autoimmunity 1998; 28:139-150.
64. Thomas SE, Lombardi D, Giachelli C, Bohle A, Johnson RJ. Osteopontin expression, tubulointerstitial disease, and essential hypertension. Am J Hypertens 1998; 11:954-961.
65. Persy VP, Verstrepen WA, Ysebaert DK, De Greef KE, De Broe ME. Differences in osteopontin up-regulation between proximal and distal tubules after renal ischemia/reperfusion. Kidney Int 1999; 56:601-611.
66. Yu XQ, Wu LL, Huang XR, Yang N, Gilbert RE, Cooper ME, et al. Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II. Kidney Int 2000; 58:1469-1480.
67. Hartner A, Porst M, Gauer S, Prols F, Veelken R, Hilgers KF. Glomerular osteopontin expression and macrophage infiltration in glomerulosclerosis of DOCA-salt rats. Am J Kidney Dis 2001; 38:153-164.